{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T01:21:23Z","timestamp":1771636883089,"version":"3.50.1"},"reference-count":103,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2015,7,1]],"date-time":"2015-07-01T00:00:00Z","timestamp":1435708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,7,1]],"date-time":"2015-07-01T00:00:00Z","timestamp":1435708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T00:00:00Z","timestamp":1692662400000},"content-version":"vor","delay-in-days":2974,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.1007\/s13311-015-0359-5","type":"journal-article","created":{"date-parts":[[2015,5,18]],"date-time":"2015-05-18T11:45:36Z","timestamp":1431949536000},"page":"572-583","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":51,"title":["Tuberous Sclerosis: A New Frontier in Targeted Treatment of Autism"],"prefix":"10.1016","volume":"12","author":[{"given":"Peter E.","family":"Davis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jurriaan M.","family":"Peters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Darcy A.","family":"Krueger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mustafa","family":"Sahin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1007\/s13311-015-0359-5_bib1","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/j.1749-6632.1991.tb37754.x","article-title":"Epidemiology of tuberous sclerosis","volume":"615","author":"Osborne","year":"1991","journal-title":"Ann N Y Acad Sci"},{"key":"10.1007\/s13311-015-0359-5_bib2","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S0140-6736(08)61279-9","article-title":"Tuberous sclerosis","volume":"372","author":"Curatolo","year":"2008","journal-title":"Lancet"},{"key":"10.1007\/s13311-015-0359-5_bib3","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/B978-0-444-52891-9.00038-5","article-title":"Tuberous sclerosis","volume":"111","author":"Curatolo","year":"2013","journal-title":"Handb Clin Neurol"},{"key":"10.1007\/s13311-015-0359-5_bib4","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.pediatrneurol.2013.08.002","article-title":"International Tuberous Sclerosis Complex Consensus Group. Tuberous sclerosis complex surveillance and management: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference","volume":"49","author":"Krueger","year":"2013","journal-title":"Pediatr Neurol"},{"key":"10.1007\/s13311-015-0359-5_bib5","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.pediatrneurol.2014.10.004","article-title":"Tuberous sclerosis associated neuropsychiatric disorders (TAND) and the TAND Checklist","volume":"52","author":"de Vries","year":"2015","journal-title":"Pediatr Neurol"},{"key":"10.1007\/s13311-015-0359-5_bib6","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1177\/0883073807309788","article-title":"Characterization of autism in young children with tuberous sclerosis complex","volume":"23","author":"Jeste","year":"2008","journal-title":"J Child Neurol"},{"key":"10.1007\/s13311-015-0359-5_bib7","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1097\/YCO.0000000000000136","article-title":"Advances in the treatment of tuberous sclerosis complex","volume":"28","author":"Leclezio","year":"2015","journal-title":"Curr Opin Psychiatry"},{"key":"10.1007\/s13311-015-0359-5_bib8","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/mp.2010.115","article-title":"Gestational immune activation and Tsc2 haploinsufficiency cooperate to disrupt fetal survival and may perturb social behavior in adult mice","volume":"17","author":"Ehninger","year":"2012","journal-title":"Mol Psychiatry"},{"key":"10.1007\/s13311-015-0359-5_bib9","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1177\/0883073807309250","article-title":"Clinical presentation and diagnosis of tuberous sclerosis complex in infancy","volume":"23","author":"Datta","year":"2008","journal-title":"J Child Neurol"},{"key":"10.1007\/s13311-015-0359-5_bib10","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1212\/WNL.0000000000000568","article-title":"Early developmental trajectories associated with ASD in infants with tuberous sclerosis complex","volume":"83","author":"Spurling Jeste","year":"2014","journal-title":"Neurology"},{"key":"10.1007\/s13311-015-0359-5_bib11","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/2040-2392-5-11","article-title":"Behavioral signatures related to genetic disorders in autism","volume":"5","author":"Bruining","year":"2014","journal-title":"Mol Autism"},{"key":"10.1007\/s13311-015-0359-5_bib12","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.cell.2012.03.017","article-title":"mTOR signaling in growth control and disease","volume":"149","author":"Laplante","year":"2012","journal-title":"Cell"},{"key":"10.1007\/s13311-015-0359-5_bib13","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.neuron.2014.09.034","article-title":"The neurology of mTOR","volume":"84","author":"Lipton","year":"2014","journal-title":"Neuron"},{"key":"10.1007\/s13311-015-0359-5_bib14","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.neuropharm.2012.05.015","article-title":"From genes to cognition in tuberous sclerosis: implications for mTOR inhibitor-based treatment approaches","volume":"68","author":"Ehninger","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1007\/s13311-015-0359-5_bib15","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.ijdevneu.2013.02.008","article-title":"A circuitry and biochemical basis for tuberous sclerosis symptoms: from epilepsy to neurocognitive deficits","volume":"31","author":"Feliciano","year":"2013","journal-title":"Int J Dev Neurosci"},{"key":"10.1007\/s13311-015-0359-5_bib16","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ijdevneu.2014.03.006","article-title":"Dysregulation of the IGF-I\/PI3K\/AKT\/mTOR signaling pathway in autism spectrum disorders","volume":"35","author":"Chen","year":"2014","journal-title":"Int J Dev Neurosci"},{"key":"10.1007\/s13311-015-0359-5_bib17","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/j.neuron.2014.07.040","article-title":"Loss of mTOR-dependent macroautophagy causes autistic-like synaptic pruning deficits","volume":"83","author":"Tang","year":"2014","journal-title":"Neuron"},{"key":"10.1007\/s13311-015-0359-5_bib18","doi-asserted-by":"crossref","first-page":"3865","DOI":"10.1093\/hmg\/ddu101","article-title":"Neuronal Tsc1\/2 complex controls autophagy through AMPK-dependent regulation of ULK1","volume":"23","author":"Di Nardo","year":"2014","journal-title":"Hum Mol Genet"},{"key":"10.1007\/s13311-015-0359-5_bib19","doi-asserted-by":"crossref","first-page":"5926","DOI":"10.1523\/JNEUROSCI.0778-09.2009","article-title":"Tuberous sclerosis complex activity is required to control neuronal stress responses in an mTOR-dependent manner","volume":"29","author":"Di Nardo","year":"2009","journal-title":"J Neurosci"},{"key":"10.1007\/s13311-015-0359-5_bib20","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.neuroscience.2013.07.037","article-title":"Focal malformations of cortical development: new vistas for molecular pathogenesis","volume":"252","author":"Lim","year":"2013","journal-title":"Neuroscience"},{"key":"10.1007\/s13311-015-0359-5_bib21","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.tins.2009.11.003","article-title":"mTOR signaling: At the crossroads of plasticity, memory and disease","volume":"33","author":"Hoeffer","year":"2010","journal-title":"Trends Neurosci"},{"key":"10.1007\/s13311-015-0359-5_bib22","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.nurt.2010.05.001","article-title":"Targeted treatments for cognitive and neurodevelopmental disorders in tuberous sclerosis complex","volume":"7","author":"de Vries","year":"2010","journal-title":"Neurotherapeutics"},{"key":"10.1007\/s13311-015-0359-5_bib23","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.cell.2008.10.017","article-title":"The autistic neuron: troubled translation?","volume":"13","author":"Kelleher","year":"2008","journal-title":"Cell"},{"key":"10.1007\/s13311-015-0359-5_bib24","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/nature10658","article-title":"Mutations causing syndromic autism define an axis of synaptic pathophysiology","volume":"480","author":"Auerbach","year":"2011","journal-title":"Nature"},{"key":"10.1007\/s13311-015-0359-5_bib25","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3389\/fnmol.2013.00019","article-title":"Autism spectrum disorder causes, mechanisms, and treatments: focus on neuronal synapses","volume":"6","author":"Won","year":"2013","journal-title":"Front Mol Neurosci"},{"key":"10.1007\/s13311-015-0359-5_bib26","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/j.nbd.2011.12.028","article-title":"Metabotropic glutamate receptor-dependent long-term depression is impaired due to elevated ERK signaling in the DeltaRG mouse model of tuberous sclerosis complex","volume":"45","author":"Chevere-Torres","year":"2012","journal-title":"Neurobiol Dis"},{"key":"10.1007\/s13311-015-0359-5_bib27","doi-asserted-by":"crossref","first-page":"6352","DOI":"10.1523\/JNEUROSCI.0995-04.2004","article-title":"Activation of the phosphoinositide 3-kinase-Akt-mammalian target of rapamycin signaling pathway is required for metabotropic glutamate receptor-dependent long-term depression","volume":"24","author":"Hou","year":"2004","journal-title":"J Neurosci"},{"key":"10.1007\/s13311-015-0359-5_bib28","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1038\/nn1566","article-title":"Regulation of neuronal morphology and function by the tumor suppressors Tsc1 and Tsc2","volume":"8","author":"Tavazoie","year":"2005","journal-title":"Nat Neurosci"},{"key":"10.1007\/s13311-015-0359-5_bib29","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.2005832","article-title":"Reciprocal signaling between translational control pathways and synaptic proteins in autism spectrum disorders","volume":"7","author":"Santini","year":"2014","journal-title":"Sci Signal"},{"key":"10.1007\/s13311-015-0359-5_bib30","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/nature11310","article-title":"Autistic-like behaviour and cerebellar dysfunction in Purkinje cell Tsc1 mutant mice","volume":"488","author":"Tsai","year":"2012","journal-title":"Nature"},{"key":"10.1007\/s13311-015-0359-5_bib31","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.nbd.2007.07.015","article-title":"Abnormal glutamate homeostasis and impaired synaptic plasticity and learning in a mouse model of tuberous sclerosis complex","volume":"28","author":"Zeng","year":"2007","journal-title":"Neurobiol Dis"},{"key":"10.1007\/s13311-015-0359-5_bib32","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.neuron.2013.03.017","article-title":"Excitatory\/inhibitory synaptic imbalance leads to hippocampal hyperexcitability in mouse models of tuberous sclerosis","volume":"78","author":"Bateup","year":"2013","journal-title":"Neuron"},{"key":"10.1007\/s13311-015-0359-5_bib33","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.pediatrneurol.2014.10.028","article-title":"Mechanistic target of rapamycin (mTOR) in tuberous sclerosis complex-associated epilepsy","volume":"52","author":"Curatolo","year":"2014","journal-title":"Pediatr Neurol"},{"key":"10.1007\/s13311-015-0359-5_bib34","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s00401-013-1085-x","article-title":"Evolving neurobiology of tuberous sclerosis complex","volume":"125","author":"Crino","year":"2013","journal-title":"Acta Neuropathol"},{"key":"10.1007\/s13311-015-0359-5_bib35","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1093\/brain\/awf124","article-title":"Neuro-epileptic determinants of autism spectrum disorders in tuberous sclerosis complex","volume":"125","author":"Bolton","year":"2002","journal-title":"Brain"},{"key":"10.1007\/s13311-015-0359-5_bib36","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1177\/08830738060210100301","article-title":"Cerebellar lesions in tuberous sclerosis complex: neurobehavioral and neuroimaging correlates","volume":"21","author":"Eluvathingal","year":"2006","journal-title":"J Child Neurol"},{"key":"10.1007\/s13311-015-0359-5_bib37","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1023\/A:1005679108529","article-title":"Autism and the cerebellum: evidence from tuberous sclerosis","volume":"30","author":"Weber","year":"2000","journal-title":"J Autism Dev Disord"},{"key":"10.1007\/s13311-015-0359-5_bib38","doi-asserted-by":"crossref","first-page":"5546","DOI":"10.1523\/JNEUROSCI.5540-06.2007","article-title":"A mouse model of tuberous sclerosis: neuronal loss of Tsc1 causes dysplastic and ectopic neurons, reduced myelination, seizure activity, and limited survival","volume":"27","author":"Meikle","year":"2007","journal-title":"J Neurosci"},{"key":"10.1007\/s13311-015-0359-5_bib39","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.acra.2011.08.016","article-title":"Loss of white matter microstructural integrity is associated with adverse neurological outcome in tuberous sclerosis complex","volume":"19","author":"Peters","year":"2012","journal-title":"Acad Radiol"},{"key":"10.1007\/s13311-015-0359-5_bib40","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1093\/cercor\/bhs135","article-title":"Impaired language pathways in tuberous sclerosis complex patients with autism spectrum disorders","volume":"23","author":"Lewis","year":"2013","journal-title":"Cereb Cortex"},{"key":"10.1007\/s13311-015-0359-5_bib41","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.conb.2007.01.009","article-title":"Autism spectrum disorders: developmental disconnection syndromes","volume":"17","author":"Geschwind","year":"2007","journal-title":"Curr Opin Neurobiol"},{"key":"10.1007\/s13311-015-0359-5_bib42","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.bandc.2010.10.005","article-title":"Distortions and disconnections: disrupted brain connectivity in autism","volume":"75","author":"Wass","year":"2011","journal-title":"Brain Cogn"},{"key":"10.1007\/s13311-015-0359-5_bib43","doi-asserted-by":"crossref","first-page":"583","DOI":"10.2217\/fnl.13.37","article-title":"Diffusion tensor imaging and related techniques in tuberous sclerosis complex: review and future directions","volume":"8","author":"Peters","year":"2013","journal-title":"Future Neurol"},{"key":"10.1007\/s13311-015-0359-5_bib44","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1007\/s10519-010-9399-0","article-title":"Epilepsy and Tsc2 haploinsufficiency lead to autistic-like social deficit behaviors in rats","volume":"41","author":"Waltereit","year":"2011","journal-title":"Behav Genet"},{"key":"10.1007\/s13311-015-0359-5_bib45","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1212\/01.wnl.0000280579.04974.c0","article-title":"Cognitive impairment in tuberous sclerosis complex is a multifactorial condition","volume":"70","author":"Jansen","year":"2008","journal-title":"Neurology"},{"key":"10.1007\/s13311-015-0359-5_bib46","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.ejpn.2011.03.010","article-title":"Antiepileptic treatment before the onset of seizures reduces epilepsy severity and risk of mental retardation in infants with tuberous sclerosis complex","volume":"15","author":"J\u00f3\u017awiak","year":"2011","journal-title":"Eur J Paediatr Neurol"},{"key":"10.1007\/s13311-015-0359-5_bib47","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.ejpn.2013.12.006","article-title":"EEG abnormalities preceding the epilepsy onset in tuberous sclerosis complex patients\u2014a prospective study of 5 patients","volume":"18","author":"Domanska-Pakiela","year":"2014","journal-title":"Eur J Paediatr Neurol"},{"key":"10.1007\/s13311-015-0359-5_bib48","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/dmcn.12044","article-title":"Understanding relationships between autism, intelligence, and epilepsy: a cross-disorder approach","volume":"55","author":"van Eeghen","year":"2013","journal-title":"Dev Med Child Neurol"},{"key":"10.1007\/s13311-015-0359-5_bib49","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.yebeh.2012.01.015","article-title":"Epilepsy and autism: is there a special relationship?","volume":"23","author":"Berg","year":"2012","journal-title":"Epilepsy Behav"},{"key":"10.1007\/s13311-015-0359-5_bib50","article-title":"Clinical characteristics of children and young adults with co-occurring autism spectrum disorder and epilepsy","author":"El","year":"2015","journal-title":"Epilepsy Behav"},{"key":"10.1007\/s13311-015-0359-5_bib51","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.nurt.2010.05.003","article-title":"Immune dysfunction in autism: a pathway to treatment","volume":"7","author":"Careaga","year":"2010","journal-title":"Neurotherapeutics"},{"key":"10.1007\/s13311-015-0359-5_bib52","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1517\/14728222.2012.677439","article-title":"An overview of the mTOR pathway as a target in cancer therapy","volume":"16","author":"Gentzler","year":"2012","journal-title":"Expert Opin Ther Targets"},{"key":"10.1007\/s13311-015-0359-5_bib53","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.2217\/pgs.13.143","article-title":"Tailoring mTOR-based therapy: molecular evidence and clinical challenges","volume":"14","author":"Santulli","year":"2013","journal-title":"Pharmacogenomics"},{"key":"10.1007\/s13311-015-0359-5_bib54","doi-asserted-by":"crossref","first-page":"8432","DOI":"10.1523\/JNEUROSCI.1105-14.2014","article-title":"Balanced mTORC1 activity in oligodendrocytes is required for accurate CNS myelination","volume":"34","author":"Lebrun-Julien","year":"2014","journal-title":"J Neurosci"},{"key":"10.1007\/s13311-015-0359-5_bib55","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.neuron.2013.03.030","article-title":"Temporal and mosaic Tsc1 deletion in the developing thalamus disrupts thalamocortical circuitry, neural function, and behavior","volume":"78","author":"Normand","year":"2013","journal-title":"Neuron"},{"key":"10.1007\/s13311-015-0359-5_bib56","doi-asserted-by":"crossref","first-page":"3817","DOI":"10.1002\/cne.23380","article-title":"Comparative analysis of Tsc1 and Tsc2 single and double radial glial cell mutants","volume":"521","author":"Mietzsch","year":"2013","journal-title":"J Comp Neurol"},{"key":"10.1007\/s13311-015-0359-5_bib57","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.nbd.2012.10.014","article-title":"Loss of Tsc2 in Purkinje cells is associated with autistic-like behavior in a mouse model of tuberous sclerosis complex","volume":"51","author":"Reith","year":"2013","journal-title":"Neurobiol Dis"},{"key":"10.1007\/s13311-015-0359-5_bib58","first-page":"1185","article-title":"Timing of mTOR activation affects tuberous sclerosis complex neuropathology in mouse models","volume":"6","author":"Magri","year":"2013","journal-title":"Dis Model Mech"},{"key":"10.1007\/s13311-015-0359-5_bib59","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1093\/cercor\/bhr300","article-title":"GABAergic interneuron development and function is modulated by the Tsc1 gene","volume":"22","author":"Fu","year":"2012","journal-title":"Cereb Cortex"},{"key":"10.1007\/s13311-015-0359-5_bib60","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.nbd.2011.08.024","article-title":"Neuronal and glia abnormalities in Tsc1-deficient forebrain and partial rescue by rapamycin","volume":"45","author":"Carson","year":"2012","journal-title":"Neurobiol Dis"},{"key":"10.1007\/s13311-015-0359-5_bib61","doi-asserted-by":"crossref","first-page":"4286","DOI":"10.1093\/hmg\/dds262","article-title":"Graded loss of tuberin in an allelic series of brain models of TSC correlates with survival, and biochemical, histological and behavioral features","volume":"21","author":"Yuan","year":"2012","journal-title":"Hum Mol Genet"},{"key":"10.1007\/s13311-015-0359-5_bib62","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.stem.2011.09.008","article-title":"Sustained activation of mTOR pathway in embryonic neural stem cells leads to development of tuberous sclerosis complex-associated lesions","volume":"9","author":"Magri","year":"2011","journal-title":"Cell Stem Cell"},{"key":"10.1007\/s13311-015-0359-5_bib63","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1101\/gad.16750211","article-title":"Tsc1 mutant neural stem\/progenitor cells exhibit migration deficits and give rise to subependymal lesions in the lateral ventricle","volume":"25","author":"Zhou","year":"2011","journal-title":"Genes Dev"},{"key":"10.1007\/s13311-015-0359-5_bib64","doi-asserted-by":"crossref","first-page":"E1070","DOI":"10.1073\/pnas.1106454108","article-title":"Regulable neural progenitor-specific Tsc1 loss yields giant cells with organellar dysfunction in a model of tuberous sclerosis complex","volume":"108","author":"Goto","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1007\/s13311-015-0359-5_bib65","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1093\/hmg\/ddq491","article-title":"Tsc2 gene inactivation causes a more severe epilepsy phenotype than Tsc1 inactivation in a mouse model of tuberous sclerosis complex","volume":"20","author":"Zeng","year":"2011","journal-title":"Hum Mol Genet"},{"key":"10.1007\/s13311-015-0359-5_bib66","doi-asserted-by":"crossref","first-page":"5422","DOI":"10.1523\/JNEUROSCI.0955-08.2008","article-title":"Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: effects on mTORC1 and Akt signaling lead to improved survival and function","volume":"28","author":"Meikle","year":"2008","journal-title":"J Neurosci"},{"key":"10.1007\/s13311-015-0359-5_bib67","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/nm1788","article-title":"Reversal of learning deficits in a Tsc2+\/- mouse model of tuberous sclerosis","volume":"14","author":"Ehninger","year":"2008","journal-title":"Nat Med"},{"key":"10.1007\/s13311-015-0359-5_bib68","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1093\/hmg\/ddp025","article-title":"Loss of Tsc2 in radial glia models the brain pathology of tuberous sclerosis complex in the mouse","volume":"18","author":"Way","year":"2009","journal-title":"Hum Mol Genet"},{"key":"10.1007\/s13311-015-0359-5_bib69","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1002\/ana.21331","article-title":"Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex","volume":"63","author":"Zeng","year":"2008","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-015-0359-5_bib70","article-title":"Vigabatrin inhibits seizures and mTOR pathway activation in a mouse model of tuberous sclerosis complex","volume":"8","author":"Zhang","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1007\/s13311-015-0359-5_bib71","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/ana.10283","article-title":"Astrocyte-specific TSC1 conditional knockout mice exhibit abnormal neuronal organization and seizures","volume":"52","author":"Uhlmann","year":"2002","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-015-0359-5_bib72","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0035885","article-title":"The interaction between early life epilepsy and autistic-like behavioral consequences: a role for the mammalian target of rapamycin (mTOR) pathway","volume":"7","author":"Talos","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1007\/s13311-015-0359-5_bib73","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.nbd.2014.10.004","article-title":"Seizure-dependent mTOR activation in 5-HT neurons promotes autism-like behaviors in mice","volume":"73","author":"McMahon","year":"2015","journal-title":"Neurobiol Dis"},{"key":"10.1007\/s13311-015-0359-5_bib74","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1002\/ana.20784","article-title":"Rapamycin causes regression of astrocytomas in tuberous sclerosis complex","volume":"59","author":"Franz","year":"2006","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-015-0359-5_bib75","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1056\/NEJMoa063564","article-title":"Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis","volume":"358","author":"Bissler","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1007\/s13311-015-0359-5_bib76","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0023379","article-title":"Multicenter phase 2 trial of sirolimus for tuberous sclerosis: kidney angiomyolipomas and other tumors regress and VEGF- D levels decrease","volume":"6","author":"Dabora","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1007\/s13311-015-0359-5_bib77","doi-asserted-by":"crossref","first-page":"4071","DOI":"10.1158\/1078-0432.CCR-11-0445","article-title":"Sirolimus therapy for angiomyolipoma in tuberous sclerosis and sporadic lymphangioleiomyomatosis: a phase 2 trial","volume":"17","author":"Davies","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1007\/s13311-015-0359-5_bib78","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1056\/NEJMoa1100391","article-title":"Efficacy and safety of sirolimus in lymphangioleiomyomatosis","volume":"364","author":"McCormack","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1007\/s13311-015-0359-5_bib79","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1056\/NEJMoa1001671","article-title":"Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis","volume":"363","author":"Krueger","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1007\/s13311-015-0359-5_bib80","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1212\/WNL.0b013e3182815428","article-title":"Everolimus long-term safety and efficacy in subependymal giant cell astrocytoma","volume":"80","author":"Krueger","year":"2013","journal-title":"Neurology"},{"key":"10.1007\/s13311-015-0359-5_bib81","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0140-6736(12)61134-9","article-title":"Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial","volume":"381","author":"Franz","year":"2013","journal-title":"Lancet"},{"key":"10.1007\/s13311-015-0359-5_bib82","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/S1470-2045(14)70489-9","article-title":"Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of the randomised EXIST-1 study","volume":"15","author":"Franz","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1007\/s13311-015-0359-5_bib83","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0140-6736(12)61767-X","article-title":"Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"381","author":"Bissler","year":"2013","journal-title":"Lancet"},{"key":"10.1007\/s13311-015-0359-5_bib84","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1177\/0883073808324535","article-title":"Rapamycin reduces seizure frequency in tuberous sclerosis complex","volume":"24","author":"Muncy","year":"2009","journal-title":"J Child Neurol"},{"key":"10.1007\/s13311-015-0359-5_bib85","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1212\/WNL.0b013e318247ca8d","article-title":"Everolimus alters white matter diffusion in tuberous sclerosis complex","volume":"78","author":"Tillema","year":"2012","journal-title":"Neurology"},{"key":"10.1007\/s13311-015-0359-5_bib86","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.ejpn.2013.03.002","article-title":"Long-term effect of everolimus on epilepsy and growth in children under 3 years of age treated for subependymal giant cell astrocytoma associated with tuberous sclerosis complex","volume":"17","author":"Kotulska","year":"2013","journal-title":"Eur J Paediatr Neurol"},{"key":"10.1007\/s13311-015-0359-5_bib87","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.ejpn.2013.06.002","article-title":"Everolimus in tuberous sclerosis patients with intractable epilepsy: a treatment option?","volume":"17","author":"Wiegand","year":"2013","journal-title":"Eur J Paediatr Neurol"},{"key":"10.1007\/s13311-015-0359-5_bib88","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s00381-013-2185-6","article-title":"Rapamycin has a beneficial effect on controlling epilepsy in children with tuberous sclerosis complex: results of 7 children from a cohort of 86","volume":"30","author":"Canpolat","year":"2014","journal-title":"Childs Nerv Syst"},{"key":"10.1007\/s13311-015-0359-5_bib89","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/j.jpeds.2013.12.053","article-title":"Mammalian target of rapamycin inhibitors for intractable epilepsy and subependymal giant cell astrocytomas in tuberous sclerosis complex","volume":"164","author":"Cardamone","year":"2014","journal-title":"J Pediatr"},{"key":"10.1007\/s13311-015-0359-5_bib90","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1002\/ana.23960","article-title":"Everolimus treatment of refractory epilepsy in tuberous sclerosis complex","volume":"74","author":"Krueger","year":"2013","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-015-0359-5_bib91","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1177\/104012371102300405","article-title":"Psychiatric comorbidity and treatment response in patients with tuberous sclerosis complex","volume":"23","author":"Chung","year":"2011","journal-title":"Ann Clin Psychiatry"},{"issue":"Suppl","key":"10.1007\/s13311-015-0359-5_bib92","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1600-0404.2011.01596.x","article-title":"Mechanism of action of vigabatrin: correcting misperceptions","author":"Ben-Menachem","year":"2011","journal-title":"Acta Neurol Scand"},{"key":"10.1007\/s13311-015-0359-5_bib93","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/j.1528-1167.2008.01988.x","article-title":"Vigabatrin: 2008 update","volume":"50","author":"Willmore","year":"2009","journal-title":"Epilepsia"},{"key":"10.1007\/s13311-015-0359-5_bib94","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1111\/j.1528-1157.1999.tb02049.x","article-title":"Randomised, placebo-controlled study of vigabatrin as first-line treatment of infantile spasms","volume":"40","author":"Appleton","year":"1999","journal-title":"Epilepsia"},{"key":"10.1007\/s13311-015-0359-5_bib95","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1212\/WNL.57.8.1416","article-title":"US Infantile Spasms Vigabatrin Study Group, Randomized trial of vigabatrin in patients with infantile spasms","volume":"57","author":"Elterman","year":"2001","journal-title":"Neurology"},{"key":"10.1007\/s13311-015-0359-5_bib96","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1111\/j.1528-1157.1997.tb00063.x","article-title":"Vigabatrin versus ACTH as first-line treatment for infantile spasms: a randomized, prospective study","volume":"38","author":"Vigevano","year":"1997","journal-title":"Epilepsia"},{"key":"10.1007\/s13311-015-0359-5_bib97","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1177\/088307389901400201","article-title":"Vigabatrin in the treatment of infantile spasms in tuberous sclerosis: literature review","volume":"14","author":"Hancock","year":"1999","journal-title":"J Child Neurol"},{"key":"10.1007\/s13311-015-0359-5_bib98","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S0920-1211(96)01006-6","article-title":"Randomized trial comparing vigabatrin and hydrocortisone in infantile spasms due to tuberous sclerosis","volume":"26","author":"Chiron","year":"1997","journal-title":"Epilepsy Res"},{"key":"10.1007\/s13311-015-0359-5_bib99","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ejpn.2009.03.003","article-title":"Early control of seizures improves long-term outcome in children with tuberous sclerosis complex","volume":"14","author":"Bombardieri","year":"2010","journal-title":"Eur J Paediatr Neurol"},{"key":"10.1007\/s13311-015-0359-5_bib100","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0920-1211(99)00082-0","article-title":"Mental and behavioural outcome of infantile epilepsy treated by vigabatrin in tuberous sclerosis patients","volume":"38","author":"Jambaque","year":"2000","journal-title":"Epilepsy Res"},{"key":"10.1007\/s13311-015-0359-5_bib101","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1177\/0883073812446485","article-title":"Vigabatrin and mental retardation in tuberous sclerosis: infantile spasms versus focal seizures","volume":"28","author":"Yum","year":"2013","journal-title":"J Child Neurol"},{"key":"10.1007\/s13311-015-0359-5_bib102","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/j.1528-1167.2008.01788.x","article-title":"Infantile spasms in tuberous sclerosis complex: prognostic utility of EEG","volume":"50","author":"Muzykewicz","year":"2009","journal-title":"Epilepsia"},{"key":"10.1007\/s13311-015-0359-5_bib103","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/1741-7015-11-54","article-title":"Brain functional networks in syndromic and non-syndromic autism: a graph theoretical study of EEG connectivity","volume":"11","author":"Peters","year":"2013","journal-title":"BMC Med"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-015-0359-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13311-015-0359-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923016045?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923016045?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-015-0359-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T07:08:34Z","timestamp":1761808114000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747923016045"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7]]},"references-count":103,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["S1878747923016045"],"URL":"https:\/\/doi.org\/10.1007\/s13311-015-0359-5","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2015,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tuberous Sclerosis: A New Frontier in Targeted Treatment of Autism","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s13311-015-0359-5","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 The American Society for Experimental NeuroTherapeutics, Inc. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}